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Abstract Carmustine wafers (CW; Gliadel wafers) are
approved to treat newly-diagnosed high-grade glioma
(HGG) and recurrent glioblastoma. Widespread use has been
limited for several reasons, including concern that their use
may preclude enrollment in subsequent clinical trials due to
uncertainty about confounding of results and potential tox-
icities. This meta-analysis estimated survival following
treatment with CW for HGG. A literature search identified
relevant studies. Overall survival (OS), median survival, and
adverse events (AEs) were summarized. Analysis of vari-
ance evaluated effects of treatment (CW vs non-CW) and
diagnosis (new vs recurrent) on median survival. The ana-
lysis included 62 publications, which reported data for 60
studies (CW: n = 3,162; non-CW: n = 1,736). For newly-
diagnosed HGG, 1-year OS was 67 % with CW and 48 %
without; 2-year OS was 26 and 15 %, respectively; median
survival was 16.4 ± 21.6 months and 13.1 ± 29.9 months,
respectively. For recurrent HGG, 1-year OS was 37 % with
CW and 34 % without; 2-year OS was 15 and 12 %,
respectively; median survival was 9.7 ± 20.9 months and
8.6 ± 22.6 months, respectively. Effects of treatment
(longer median survival with CW than without; P = 0.043)
and diagnosis (longer median survival for newly-diagnosed
HGG than recurrent; P \ 0.001) on median survival were
significant, with no significant treatment-by-diagnosis
interaction (P = 0.620). The most common AE associated
with wafer removal was surgical site infection (SSI); the
most common AEs for repeat surgery were mass effect, SSI,
hydrocephalus, cysts in resection cavity, acute hematoma,
wound healing complications, and brain necrosis. These data
may be useful in the context of utilizing CW in HGG
management, and in designing future clinical trials to allow
CW-treated patients to participate in experimental protocols.
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Introduction
High-grade gliomas (HGG; WHO grade 3 or 4) account for
the majority of newly-diagnosed malignant brain tumors,
with glioblastoma multiforme (GBM) representing the
most common subtype [1]. These highly infiltrative and
aggressive tumors generally have a poor prognosis, as they
are difficult to treat and recurrence is common [2]. Treat-
ment for HGG generally includes surgical resection fol-
lowed by radiotherapy and chemotherapy [2]. In particular,
the addition of the alkylating agent temozolomide (TMZ)
to post-surgical radiotherapy and as adjuvant therapy has
become standard treatment for many patients with HGG [2,
3]. Factors associated with prolonged survival include
complete resection (C98 % of tumor volume) [4], younger
age [5], better performance status [5], MGMT promoter
status [6, 7], oligodendroglial phenotype [5], p53 mutation
[8], and IDH1 mutation [9].
Carmustine wafer (CW) implant (Gliadel Wafer, Arbor
Pharmaceuticals, LLC, Atlanta, GA) is approved for treat-
ment of newly-diagnosed HGG as an adjunct to surgery and
radiation and for treatment of recurrent GBM as an adjunct to
surgery [10]. Local chemotherapy with CW was shown to
significantly increase survival compared with placebo in
newly-diagnosed HGG [11, 12] and in recurrent GBM [13].
Risks associated with CW include cerebral edema, healing
abnormalities, intracranial infections, seizures, intracranial
hypertension, and cerebrospinal fluid leaks [14].
Treatment guidelines recommend CW as appropriate
for some patients (e.g., patients in whom near total
resection is feasible [Category 2B recommendation] [2] or
in whom craniotomy is indicated [Level II recommenda-
tion] [15]); however, questions remain as to its optimal
use. For example, randomized controlled trials (RCT)
comparing CW and TMZ as single treatments have not
been conducted, and while several reports on the use of
TMZ following CW implantation have been published
(see review by Dixit et al. [16]), there remain concerns
about the safety of this approach [2]. Currently, many
clinical trials of new chemotherapies exclude patients
treated with CW [2, 17] because of concerns about
potential toxicities, confounding of results (e.g., due to
wafer-induced imaging changes), and a paucity of reliable
survival statistics. More reliable data regarding expected
survival times with CW might be helpful in the context of
designing future clinical trials, so that new protocols
might accommodate the use of CW as part of a compre-
hensive approach utilizing multiple treatment modalities
maximizing benefit to patients.
This meta-analysis was designed to estimate survival
times for patients treated with CW for newly-diagnosed or
recurrent HGG, using data from published studies.
Methods
Search strategy and study selection
A literature search was conducted in January, 2014 using
Medline (includes PubMed), Embase, and BIOSIS, with the
following search criteria: gliadel OR [(‘‘BCNU’’ OR car-
mustine) AND (polymer OR polymers OR wafer* OR po-
lifeprosan OR interstitial)] AND (glioma OR glioblastoma);
no restrictions on publication date were used. The abstract of
each publication was screened to determine relevance. Much
of the published evidence on CW is derived from retro-
spective studies of heterogeneous populations and varying
treatment regimens, which generally precludes inclusion of
these publications in meta-analyses. However, in an effort to
utilize as much of the available data as possible and increase
the generalizability of our results, we chose to exclude only
preclinical or phase 1 studies, individual case reports, or
small case series (n \ 10); also excluded were review arti-
cles, editorials, and studies of carmustine administered in a
formulation other than wafers. Each remaining publication
was reviewed to determine if overall survival or selected
safety/toxicity outcomes (seizures, wound healing compli-
cations, infection, or mass effect) were reported for patients
treated with CW. Relevant congress abstracts published in
2009 or later were identified (via the Northern Light database
in addition to sources listed above) and screened using the
same process and criteria described above. Abstracts of
studies with full results published were also excluded.
Data collection
Data were extracted and reviewed. The following were
collected: (1) characteristics of study participants, includ-
ing age, sex, diagnosis (new or recurrent), tumor grade
(grade 3 or 4 vs grade 4 only); (2) study treatment (specific
treatment regimens, general categories of CW alone,
CW ? other treatment(s), no CW, radiotherapy use); (3)
survival outcomes (1-, 2-, and 3-year survival rate; median
survival time); (4) safety outcomes (adverse events [AEs],
deaths due to AEs, wafer removal, repeat surgery).
Statistical analyses
Overall survival (OS) rates at 1, 2, and 3 years, and median
survival time were summarized by tumor grade (grade 3 or
4 vs grade 4 only), by new or recurrent diagnosis, and by
use of CW with or without TMZ. A factorial analysis of
variance was performed to evaluate the effects of treatment
(CW vs no CW), diagnosis (new vs recurrent), and use of
TMZ (among CW-treated patients) on median survival. All
statistical analyses including tests of hypotheses and P-
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values are based on weighted statistics, where the weights
were derived from the total safety or efficacy sample size.
Statistical significance for all weighted statistical tests were
set at P B 0.05. No Bonferroni correction for multiple
inferences was applied. All analyses were performed using
SAS (version 9.2). The incidence of safety outcomes in
patients treated with CW was summarized.
Results
Search results
The initial PubMed search retrieved 350 possible references.
Twenty-five duplicate articles were excluded. Based on
initial screening of the article abstracts, 269 were excluded
(100 were reviews or editorials; 83 did not evaluate CW; 56
were preclinical or phase 1 studies; 22 were individual case
reports or small case series; 3 did not evaluate patients with
HGG; 3 were pediatric studies; and 2 were secondary or
subgroup analyses of published studies). The full text of the
remaining 56 references were obtained and reviewed. Six-
teen of these references were excluded from the analyses,
leaving 40 published reports that were included in the sur-
vival or safety analyses. The search of the abstract database
identified 22 abstracts for analysis (Fig. 1). Thus, a total of 62
publications were included (Table 1) [6, 11–13, 18–75].
Publication and population characteristics
The 62 publications in this analysis reported data for 60
separate studies; one study (Westphal 2003 [12]) was
reported in 3 publications: the primary study report and 2
follow-up analyses [36, 74]. Thus, in all, 60 different study
populations were included. In all analyses, sample sizes
were calculated for each variable. The total number of
patients treated with CW in 60 studies was 3,162
(mean ± SD sample size = 53 ± 47, range 10–288). The
total number of patients treated without CW in 17 studies
was 1,736 (mean ± SD sample size = 102 ± 167, range
10–725). A total of 3,071 patients treated with CW and
1,663 patients without CW were evaluated for safety;
efficacy populations were 2,637 and 1,685, respectively (all
analyses were based on the number of patients with data for
a specific outcome). The mean ± SD age of patients in the
25 studies reporting mean age was 55 ± 37 years (range
from 33 studies reporting range = 17–83 years).
Thirty-eight studies were retrospective studies, seven studies
were prospective observational studies, and fifteen were phase
1/2 through 3 clinical trials and/or randomized controlled trials.
Twenty-eight studies included only newly-diagnosed
patients, 16 studies included only recurrent patients, and
14 studies included both newly-diagnosed and recurrent
patients, while 2 studies [38, 45]) did not specify.
Thirty-three studies included patients with grade 4
tumors only; 25 studies included patients with grade 3
or grade 4 HGG; tumor grade was not stated for 2
studies.
Study treatments (for patients treated with CW) were
listed as: Surgery ? CW-only in 19 studies, Sur-
gery ? CW ? other treatment(s) in 28 studies, both Sur-
gery ? CW-only, and Surgery ? CW ? other treatments
in 10 studies, and not stated in 2 studies. Radiotherapy was
used with CW in 38 (63 %) studies, chemotherapy with
TMZ was used with CW in 32 (53 %) studies, and other
chemotherapy was used in 9 (15 %) studies.
Efficacy
Overall survival
OS was summarized separately for patients with newly-
diagnosed HGG and for those with recurrent HGG. Among
patients with newly-diagnosed HGG, OS at 1, 2, and
3 years was numerically greater for patients who received
treatment with CW compared with those who did not;
among those treated with CW, OS was numerically higher
for patients who also received TMZ compared with those
who did not (Fig. 2a). The same general pattern was
observed when data from only patients with grade 4 tumors
were analyzed (Fig. 2b).
Survival among patients with recurrence was based on
time from diagnosis of surgery for recurrence. Among
patients with recurrent HGG, OS at 1, 2, and 3 years was
numerically greater for patients treated with CW com-
pared with those who were not; among those treated with
CW, OS was numerically higher for patients who also
received TMZ compared with those who did not (Fig. 3a).
Results were similar in the analysis of data from only
patients with grade 4 tumors (Fig. 3b). In both cases,
results for patients treated with CW ? TMZ should be
interpreted with caution, as they are based on a very
limited sample of patients.
Median survival
Median survival for patients with newly-diagnosed and
recurrent HGG is shown in Fig. 4a (grade 3 or 4) and
Fig. 4b (grade 4 only). Analysis of median survival data
showed a significant effect of treatment (median survival
was longer with CW than without; P = 0.043) and diag-
nosis (median survival was longer for newly diagnosed
HGG than recurrent HGG; P \ 0.001), with no treatment-
by-diagnosis interaction (P = 0.620); the effect of TMZ
was also significant (P \ 0.001).
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Safety
There were 28 deaths (28/3,071; 0.91 %) reported as adverse
events (AEs) among patients receiving CW, and 34 deaths
(34/1,663; 2.0 %) among patients not receiving CW. The
single large RCT of only recurrent diagnosed patients of CW
vs cintredekin besudotox [43] had all 34 deaths in patients
who did not receive CW (34/177 = 19.2 %), and 13 deaths
among CW patients (13/92 = 14.1 %, P [ 0.05). The
remaining 15 deaths were reported in 11 studies; most
(n = 10) were among newly-diagnosed patients. Not all
studies indicated specific AEs resulting in death; among the
specific AEs that were cited (for 16 patients treated with
CW), pulmonary embolism (n = 3) and stroke (n = 2) were
the most common (all others were 1 patient each).
CW removal was performed on 12 patients (12/3,071;
0.39 %) in 5 studies, where 5 patients were recurrent
diagnosis patients. In 8 of the 12 patients, the AE term
associated with wafer removal was infection at the surgical
site.
Repeat surgeries were performed in 83 patients treated
with CW (83/3,071; 2.7 %) in 13 studies. The most com-
mon AE terms associated with repeat surgeries were sur-
gical site infection (n = 11), hydrocephalus (n = 9),
hematoma (n = 8), cysts in resection cavity (n = 7), and
wound healing complications (n = 6).
Discussion
In this meta-analysis of data from patients with newly-
diagnosed HGG treated with CW (±other adjuvant treat-
ments), median survival time was 16 months, with 1- and
2-year OS of 67 and 26 %, respectively. Among patients
from the same studies who were treated with other
modalities, median survival time was 13 months, with
1-year OS of 48 % and 2-year OS of 15 %.
As expected, OS rates were lower (1-year: 37 %; 2-year:
15 % and median survival (approximately 10 months) was
shorter among patients treated with CW with recurrent
disease relative to those with newly-diagnosed disease. The
median survival times reported here are slightly longer than
those reported in the prescribing information for CW (13.8
and 7.4 months for new and recurrent glioma, respectively)
[10], which are based on 2 phase 3 RCTs [12, 13]. This
difference may be due in part to the inclusion of TMZ and
other adjuvant treatments or advances in surgical resection
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Fig. 1 Flow diagram
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The majority studies included in this analysis enrolled
patients with grade 4 gliomas; several studies also included
patients with grade 3 gliomas, although outcomes in those
studies were not always reported separately by tumor
grade. In our analysis, survival outcomes among the subset
of patients treated with CW with grade 4 HGG were gen-
erally similar to those among all patients (i.e., patients with
grade 3 or 4 HGG).
In this analysis, survival was generally improved among
patients treated with CW who also received TMZ than
among those who received CW without TMZ. This is not
unexpected, considering the complementary mechanisms
of action of CW and TMZ, as has previously been reviewed
[76]. However, the sample sizes for these subgroups were
limited. In addition, only a few of the studies that evaluated
CW with TMZ accounted for MGMT promoter status [37,
44, 52, 62, 70]. In light of evidence that MGMT promoter
status may be a significant predictor of survival in patients
treated with CW or TMZ [6, 7], this further limits the
ability to draw definitive conclusions from these data with
regard to potential treatment-related differences in survival
benefit. An extensive exploration of molecular mechanisms
and optimization of HGG treatment in an era of personal-
ized medicine is beyond the scope of this discussion.
However, we believe that studies will need to be conducted
further evaluating the role of CW for use as part of a multi-
modal approach with the current ‘‘standard of care’’ of
newly-diagnosed GBM, i.e., radiotherapy plus TMZ, fol-
lowed by monthly adjuvant TMZ, as well as with the many
new emerging targeted therapies, including drugs such as
bevacizumab. Also in light of the newly-presented data this
past year regarding the upfront glioblastoma multiforme




























n=340 n=410 n=8 n=388 n=295 n=335 n=8 n=313 n=112 n=196 n=196 


























n=228 n=275 n=4 n=257 n=183 n=217 n=203 n=86 n=86 




Fig. 3 a, b Overall survival rates in patients with recurrent HGG
a grade 3 or 4 and b grade 4 only. CW carmustine wafer, n/a not
available, HGG high-grade glioma, TMZ temozolomide. Limited
sample size for CW ? TMZ. Survival based on time after diagnosis
of, or surgery for, recurrent disease. If the sum of the n values for
CW ? TMZ and CW without TMZ subgroups does not equal the n
for the All CW subgroup, this is due to the fact that a few studies in
the meta-analysis included some patients who received TMZ and
some who did not, but results were reported for the entire study group
(i.e., not reported separately based on use of TMZ); data from these
studies were included in the analysis for All CW, but were excluded
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n=232  n=726  n=422  n=259 n=232  n=679  n=347  n=287 n=216  n=571  n=309  n=217 
No CW All CW CW with TMZ CW without TMZ
(a)
(b)
Fig. 2 a, b Overall survival rates in patients with newly-diagnosed
HGG a grade 3 or 4 and b grade 4 only. CW carmustine wafer, HGG
high-grade glioma, TMZ temozolomide. If the sum of the n values for
CW ? TMZ and CW without TMZ subgroups does not equal the n
for the All CW subgroup, this is due to the fact that a few studies in
the meta-analysis included some patients who received TMZ and
some who did not, but results were reported for the entire study group
(i.e., not reported separately based on use of TMZ); data from these
studies were included in the analysis for All CW, but were excluded
from the with/without TMZ analyses
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the utility of CW in HGG may need to be revisited: given
the heterogeneity of HGG at a tumor biology level, it may
seem prudent to treat these tumors in a multimodality
approach fashion and utilize CW with TMZ and radio-
therapy in the appropriate patients in the upfront setting.
Among patients treated with CW, the incidence of death
reported as an AE was 0.9,\1 % of patients required wafer
removal, and approximately 3 % required repeat surgery. The
AEs/complications associated with these events were gener-
ally consistent with the known safety profile of CW (e.g.,
surgical site infection, hydrocephalus, wound healing abnor-
malities, etc.) [10, 14]. Good surgical practice should include
proper and careful technique toward ensuring a water-tight
dural closure, thus lowering the risk of known AEs.
Two meta-analyses and several reviews have been
published that summarized efficacy and safety data from
studies of CW [16, 17, 79–83]. In the most recent Cochrane
review of CW, Hart and colleagues reported significantly
increased survival with CW relative to placebo in primary
disease (HR 0.65, 95 % CI 0.48–0.86, P = 0.003), and a
non-significant difference in recurrence (HR 0.83, 95 % CI
0.62–1.10, P = 0.2). Consistent with the aims of that meta-
analysis, estimates of survival times were not calculated
and data were largely limited to those from RCTs. A recent
meta-analysis based on 19 studies that included newly-
diagnosed patients with glioblastoma who were treated
with CW found a median survival time of 16.2 months
[84]. This is consistent with our finding of 16.4 months for
the same type of patients. A number of systematic reviews
have been published that included data from multiple
studies of various designs [16, 17, 79–82]; however, again,
estimates of survival times were not calculated, as these
reviews summarized individual study data without further
analysis. The lack of similarly designed analyses in the
literature therefore limits our ability to compare our results
with many published reviews.
In contrast to previous reports, with the current meta-
analysis we sought to better characterize outcomes with
CW using data from as many studies as possible, to aid
clinicians in making treatment recommendations and to
assist researchers in developing more inclusive clinical trial
designs by providing the most comprehensive and reliable
survival-related dataset. As such, the inclusion criteria we
used in selecting studies were less restrictive than those of
more traditional meta-analyses. Thus, the heterogeneity of
the included studies in terms of study design, patient
characteristics, and study treatments (variability was pres-
ent not only between studies but within individual studies),
must be noted as a limitation. Because our analysis did not
control for the potential effects of these variables, which
can have an impact on survival outcomes, these factors
should be kept in mind when considering the results. In
addition, we did not systematically assess each study for
potential bias. The nature of the majority of studies (ret-
rospective, single-arm) largely eliminates bias in terms of
favoring one treatment over another. However, there is a
degree of selection bias inherent in the patient populations
studied; that is, patients who are candidates for CW
3 6 9 12 15
Median Survival Time (months)









3 6 9 12 15
Median Survival Time (months)











Fig. 4 a, b Median survival among patients with newly-diagnosed or
recurrent HGG a grade 3 or 4 and b grade 4 only; box plots with
average (diamond), 25th, 50th and 75th percentiles (lines of the box)
and range (minimum and maximum hash marks) are also provided for
the median survival times (months). Significant effects of treatment
(CW vs no CW; P = 0.043) and diagnosis (new diagnosis vs
recurrence; P \ 0.001) were detected, with no treatment-by-diagnosis
interaction (P = 0.620); the effect of TMZ was also significant
(P \ 0.001). CW carmustine wafer, HGG high-grade glioma, TMZ
temozolomide. Limited sample size for Recurrent/CW ? TMZ.
Survival for recurrent diagnosis based on time after diagnosis of, or
surgery for, recurrent disease
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treatment generally have better performance status and
have accessible tumors that can be almost completely
resected, and therefore a better prognosis than patients who
are not candidates for CW treatment.
In this comprehensive review of the literature on CW
and meta-analysis of published survival data, we attempted
to summarize the cumulative data of numerous studies that
have been reported over the past 18 years. Our results
highlight benefits in survival of patients in the CW arms
versus patients who did not receive CW. There was sig-
nificant effect of CW treatment on median survival
(P = 0.043), with higher OS rates for patients with new or
recurrent HGG within the cohort treated with CW.
CW is an FDA-approved treatment modality for all
newly-diagnosed HGGs, including GBM, anaplastic astro-
cytoma, anaplastic oligodendroglioma, and anaplastic oli-
goastrocytoma, as well as for recurrent GBM. It is also now
an accepted form of therapy for newly-diagnosed and
recurrent HGG in the most recent NCCN guidelines for CNS
tumors [2]. Traditionally, the use of CW has precluded
patients from accrual to many clinical trials. One frequently
cited reason for exclusion is the potential ambiguity that the
presence of the wafers have on the assessment of treatment
response (or lack thereof) on follow-up MRI scans. How-
ever, it should be considered that following the phase of the
treatment involving chemotherapy (in the time between
resection and radiotherapy), an inflammatory response
occurs, which may also contribute to the effect. In the current
era of new biologicals entering clinical trials, the combina-
tion of an active inflammatory milieu together with an
empowered immune system (e.g., dendritic cells, immune
checkpoint modulators) may have positive anti-tumor
interactions that will have to be determined in trials. Con-
sidering the recent trend toward a greater emphasis on OS
(rather than PFS), which is largely independent of imaging
measures, it may be helpful to reconsider the notion that CW
precludes any trial participation. Another important issue
contributing to reluctance to use CW involves the lack of
reliable survival data for patients treated with CW, which
might lead to confusion during the statistical analysis of the
survival data of patients in a given trial. With the publication
of this new, comprehensive dataset regarding the survival of
more than 3,000 patients treated with CW, it should be easier
to design clinical trials that can include patients who had
received CW. In addition, statisticians will now have more
reliable median survival times, 1-year survival rates, and
2-year survival rates to use for the analysis of protocols that
will allow accrual of these patients.
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